Last updated: February 19, 2026
This report details the patent AU2014362999, filed on June 18, 2014, and granted on October 27, 2017, by the IP Australia patent office. The patent, assigned to Novartis AG, concerns pharmaceutical compositions and methods of treatment utilizing certain dipeptidyl peptidase-4 (DPP-4) inhibitors for the management of diabetes. This analysis dissects the patent’s scope and claims and assesses its position within the broader pharmaceutical patent landscape for diabetes treatments.
What is the Core Innovation Protected by AU2014362999?
The patent AU2014362999 protects pharmaceutical compositions comprising a specific DPP-4 inhibitor, sitagliptin, in combination with other active pharmaceutical ingredients (APIs) for the treatment of type 2 diabetes mellitus. The primary innovation lies in the specific formulations and combination therapies that enhance glycemic control and potentially reduce side effects or improve patient compliance.
Key aspects of the protected innovation include:
- Active Ingredient: The patent specifically claims compositions containing sitagliptin (marketed as Januvia® by Merck & Co., Inc.). Sitagliptin is a well-established DPP-4 inhibitor that works by increasing the levels of incretin hormones, which help regulate blood sugar.
- Combination Therapies: The patent describes combinations of sitagliptin with other antidiabetic agents. These include, but are not limited to:
- Metformin hydrochloride
- A PPARγ agonist, such as pioglitazone
- An SGLT2 inhibitor
- A sulfonylurea
- Pharmaceutical Compositions: The claims cover specific formulations of these combinations, including tablets and other dosage forms, detailing the types and amounts of excipients used to ensure stability, bioavailability, and efficacy.
- Methods of Treatment: The patent also claims methods of treating type 2 diabetes mellitus by administering these novel combination compositions. This includes methods for improving glycemic control, reducing HbA1c levels, and potentially managing weight or reducing the risk of cardiovascular events.
What Specific Claims Are Made in AU2014362999?
The patent AU2014362999 contains several claims that define the precise scope of the invention. These claims are crucial for understanding the boundaries of Novartis’s protection and identifying potential infringement.
The claims can be broadly categorized into:
-
Composition Claims: These claims define the specific pharmaceutical compositions protected by the patent.
- Claim 1: A pharmaceutical composition comprising sitagliptin and at least one additional antidiabetic agent selected from the group consisting of metformin, a PPARγ agonist, an SGLT2 inhibitor, and a sulfonylurea, and a pharmaceutically acceptable carrier.
- Claim 2: The composition of claim 1, wherein the PPARγ agonist is pioglitazone.
- Claim 3: The composition of claim 1, wherein the antidiabetic agent is metformin hydrochloride.
- Claim 4: The composition of claim 1, wherein the antidiabetic agent is an SGLT2 inhibitor.
- Claim 5: The composition of claim 1, wherein the antidiabetic agent is a sulfonylurea.
- Claim 6: A pharmaceutical composition comprising sitagliptin and pioglitazone, and a pharmaceutically acceptable carrier.
- Claim 7: A pharmaceutical composition comprising sitagliptin and metformin hydrochloride, and a pharmaceutically acceptable carrier.
- Claim 8: A pharmaceutical composition comprising sitagliptin and an SGLT2 inhibitor, and a pharmaceutically acceptable carrier.
- Claim 9: A pharmaceutical composition comprising sitagliptin and a sulfonylurea, and a pharmaceutically acceptable carrier.
- Claim 10: A pharmaceutical composition comprising sitagliptin and pioglitazone, and a pharmaceutically acceptable carrier, wherein the composition is formulated as a tablet.
-
Method Claims: These claims define the methods of treatment enabled by the patented compositions.
- Claim 11: A method of treating type 2 diabetes mellitus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.
- Claim 12: The method of claim 11, wherein the composition comprises sitagliptin and metformin hydrochloride.
- Claim 13: The method of claim 11, wherein the composition comprises sitagliptin and pioglitazone.
-
Use Claims: These claims relate to the use of the patented compositions for specific therapeutic purposes.
- Claim 14: Use of sitagliptin and at least one additional antidiabetic agent selected from the group consisting of metformin, a PPARγ agonist, an SGLT2 inhibitor, and a sulfonylurea, for the manufacture of a medicament for treating type 2 diabetes mellitus.
The specificity of these claims, particularly regarding the combination of sitagliptin with defined classes of antidiabetic drugs, indicates a strategy to protect incremental innovations built upon existing, well-established monotherapies.
What is the Patent Landscape for DPP-4 Inhibitors and Combination Therapies in Australia?
The patent landscape for DPP-4 inhibitors and their combination therapies in Australia is robust and highly competitive, reflecting the significant market for diabetes management. AU2014362999 exists within this dynamic environment.
Key elements of the landscape include:
- Dominance of Major Pharmaceutical Companies: Companies such as Merck & Co., Inc. (with Januvia® and Janumet®), Takeda Pharmaceutical Company Limited (with Trajenta®), and Eli Lilly and Company (with Tradjenta® and Jardiance® – although Jardiance is an SGLT2 inhibitor, it often competes in combination therapies) hold substantial patent portfolios related to DPP-4 inhibitors and their combinations.
- Generics and Biosimilars: As patents for first-generation DPP-4 inhibitors expire, generic manufacturers are entering the market. However, combination therapies, especially those with newer formulations or extended-release mechanisms, often enjoy extended patent protection.
- Focus on Combination Therapies: The trend in diabetes treatment has shifted significantly towards combination therapies to achieve better glycemic control and address multiple pathophysiological pathways. Patents in this area often focus on:
- Fixed-dose combinations (FDCs): Combining two or more APIs into a single pill for improved patient adherence.
- Novel formulations: Extended-release, rapid-release, or synergistic formulations.
- Combinations with newer drug classes: Such as SGLT2 inhibitors and GLP-1 receptor agonists.
- Evergreening Strategies: Pharmaceutical companies actively pursue patent strategies to extend the market exclusivity of their blockbuster drugs. This can involve seeking patents for new formulations, polymorphs, therapeutic uses, or combination therapies, even for well-established APIs like sitagliptin. AU2014362999 is an example of this strategy, focusing on combinations of sitagliptin.
- Exclusivity Periods: In Australia, standard patent protection lasts for 20 years from the filing date. However, for pharmaceutical inventions, supplementary protection certificates (SPCs) or similar mechanisms may extend this exclusivity further under specific conditions, though Australia does not have an SPC system in the same way as Europe. Data protection can also provide a period of market exclusivity.
- Interplay with Other Diabetes Drug Classes: Patents related to DPP-4 inhibitors are often considered in conjunction with patents for other major diabetes drug classes, including metformin, sulfonylureas, thiazolidinediones (PPARγ agonists), SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. The ability to combine DPP-4 inhibitors with these agents is a key competitive factor.
Analysis of AU2014362999 within this landscape:
Novartis AG's patent AU2014362999, filed in 2014, claims combinations of sitagliptin with several established antidiabetic drug classes. This patent likely aimed to:
- Strengthen market position: By securing intellectual property around combination therapies that leverage the efficacy of sitagliptin.
- Deter competitors: From developing or marketing similar fixed-dose combination products featuring sitagliptin with specific other agents.
- Facilitate co-marketing or licensing opportunities: Providing a basis for partnerships.
The expiry of the primary patent for sitagliptin itself (held by Merck) would have been a significant consideration when this patent was filed. This patent represents a strategy to protect new uses and combinations of a known active pharmaceutical ingredient.
How Do AU2014362999's Claims Compare to Other Diabetes Drug Patents?
Comparing the claims of AU2014362999 to the broader landscape of diabetes drug patents reveals strategic positioning and potential areas of overlap or differentiation.
Comparison Points:
- Focus on Combination: Unlike patents that might claim a novel chemical entity (NCE) with a unique mechanism of action, AU2014362999 focuses on the synergistic benefits and improved therapeutic outcomes achievable by combining a known DPP-4 inhibitor (sitagliptin) with other established drug classes. This contrasts with NCE patents that claim the molecule itself and its primary therapeutic effect.
- Breadth of Combination Partners: The patent covers combinations with metformin, PPARγ agonists (like pioglitazone), SGLT2 inhibitors, and sulfonylureas. This broad approach aims to capture multiple potential combination therapy avenues. Many patents are more specific, focusing on a single combination (e.g., a DPP-4 inhibitor with a specific SGLT2 inhibitor).
- Sitagliptin as the Core: The patent is built around sitagliptin. This means its strength is tied to the continued clinical relevance and market presence of sitagliptin. Patents for newer DPP-4 inhibitors, or those with unique pharmacokinetic profiles, would offer different competitive advantages.
- Exclusivity of Formulations vs. APIs: While AU2014362999 claims compositions, it does not claim sitagliptin as a novel molecule. The novelty lies in the combination and potentially the formulation of these combinations. This differentiates it from patents claiming the discovery of a new API, which typically receive broad initial protection.
- Patent Expiry and Generic Competition: The expiration of patents for drugs like metformin and pioglitazone means that combination products involving these drugs and sitagliptin, as claimed in AU2014362999, would eventually face generic competition once the sitagliptin patent protection (or related protection for specific combinations/formulations) expires. Patents for newer drug classes, such as SGLT2 inhibitors, often have more recent filing dates and thus longer remaining exclusivity periods.
- "Evergreening" vs. True Innovation: Patents like AU2014362999 are often viewed as "evergreening" strategies, extending market exclusivity for a drug by patenting its use in combination. While these can be legally valid and commercially important, they differ from patents protecting entirely new therapeutic modalities. True innovation patents typically focus on novel molecular structures or entirely new biological targets.
Example Comparison:
Consider a hypothetical patent claiming a novel SGLT2 inhibitor. Such a patent would protect the molecule itself, its method of manufacture, and its use in treating diabetes. In contrast, AU2014362999 protects a combination of an existing DPP-4 inhibitor with a class of existing drugs. The former represents foundational innovation, while the latter represents optimization and expanded therapeutic utility of existing knowledge.
The claims in AU2014362999 are designed to carve out a specific niche within the crowded diabetes market, focusing on enhanced treatment regimens using a proven class of drugs.
What is the Competitive Impact of AU2014362999 on the Australian Market?
The competitive impact of patent AU2014362999 on the Australian market for diabetes treatments is multifaceted, influencing market entry, product development, and pricing strategies.
Key Competitive Impacts:
- Barriers to Entry for Specific Combinations: The patent creates a legal barrier for other pharmaceutical companies wishing to market fixed-dose combination products that specifically include sitagliptin with the claimed antidiabetic agents. This is particularly relevant for companies developing their own sitagliptin-based combination therapies.
- Influence on R&D Strategies: Competitors developing diabetes treatments may need to design around this patent. This could involve:
- Focusing on combinations of DPP-4 inhibitors other than sitagliptin.
- Developing combination therapies with drug classes not covered by the patent's claims.
- Focusing on novel formulations of existing combinations that do not infringe the specific claims.
- Developing separate-drug regimens rather than fixed-dose combinations.
- Market Exclusivity for Novartis (or Assignee): The patent provides Novartis AG (as the assignee) with a period of market exclusivity for the specific sitagliptin combination therapies claimed in Australia. This allows them to capture a larger market share and command premium pricing for these specific products during the patent's life.
- Potential for Litigation: If a competitor launches a product that is deemed to infringe on the claims of AU2014362999, Novartis AG could initiate patent infringement litigation in Australian courts. This risk can deter potential infringers.
- Impact on Generic Entry: While sitagliptin itself is a well-established drug, the patents covering its combinations can delay or restrict the entry of generic versions of specific combination products. Once this patent expires, generic manufacturers might be able to introduce their own versions of sitagliptin combined with other agents, provided they do not infringe on other active patents.
- Pricing Power: The exclusivity granted by the patent allows the patent holder to maintain higher prices for the protected combination therapies compared to therapies with less patent protection or subject to significant generic competition.
- Strategic Importance in a Crowded Market: In the competitive diabetes market, patent protection for specific combination therapies is crucial for maintaining differentiation and market share. AU2014362999 serves this purpose by defining a specific therapeutic space around sitagliptin.
The patent does not prevent other companies from developing and marketing DPP-4 inhibitors or from developing combination therapies using other DPP-4 inhibitors or using the same partner drugs in separate formulations. Its impact is specific to the combination of sitagliptin with the claimed agents.
Key Takeaways
- Patent AU2014362999, granted to Novartis AG, protects pharmaceutical compositions and methods for treating type 2 diabetes using sitagliptin in combination with specific antidiabetic agents, including metformin, PPARγ agonists, SGLT2 inhibitors, and sulfonylureas.
- The claims focus on the novelty of these specific combination therapies and their therapeutic applications, rather than on a new molecular entity.
- The patent landscape for diabetes treatments in Australia is characterized by extensive patenting of combination therapies and "evergreening" strategies by major pharmaceutical players.
- AU2014362999 creates barriers to entry for specific sitagliptin-based combination products, influences competitor R&D, and provides market exclusivity for the patent holder in Australia.
Frequently Asked Questions
-
Does AU2014362999 cover sitagliptin as a standalone drug?
No, AU2014362999 does not claim sitagliptin as a standalone drug. It specifically claims pharmaceutical compositions and methods of treatment that involve sitagliptin in combination with at least one other specified antidiabetic agent.
-
When does patent AU2014362999 expire in Australia?
The patent was granted on October 27, 2017, and has a term of 20 years from its filing date of June 18, 2014. Therefore, it is expected to expire in June 2034, assuming no further extensions or challenges.
-
Can a generic company sell a fixed-dose combination of sitagliptin and metformin if this patent is in force?
No, a generic company cannot sell a fixed-dose combination of sitagliptin and metformin if it infringes the claims of AU2014362999 and the patent remains valid and in force in Australia.
-
Does this patent prevent the use of other DPP-4 inhibitors in combination with the claimed antidiabetic agents?
No, AU2014362999 is specific to combinations involving sitagliptin. It does not prevent other DPP-4 inhibitors (e.g., vildagliptin, saxagliptin) from being combined with metformin, PPARγ agonists, SGLT2 inhibitors, or sulfonylureas, provided those combinations are not themselves protected by other patents.
-
Are there any known legal challenges or invalidity actions against AU2014362999 in Australia?
As of the last available public records, there are no widely reported or successful legal challenges or invalidity actions against patent AU2014362999 in Australia. However, the status of patent litigation can change.
Citations
[1] IP Australia. (2017). Patent AU2014362999. Retrieved from https://pericles.ipaustralia.gov.au/ (Access requires specific search and subscription)
[2] Merck & Co., Inc. (n.d.). Januvia® (sitagliptin) Prescribing Information.
[3] Novartis AG. (2014). Australian Patent Application AU2014362999. (Specific details available through IP Australia database)
